行情

AIM

AIM

AIM ImmunoTech Inc
AMEX

实时行情|Nasdaq Last Sale

2.110
-0.060
-2.77%
盘后: 2.160 +0.05 +2.37% 18:17 06/18 EDT
开盘
2.150
昨收
2.170
最高
2.170
最低
2.110
成交量
50.96万
成交额
--
52周最高
4.300
52周最低
1.600
市值
1.01亿
市盈率(TTM)
-5.6736
分时
5日
1月
3月
1年
5年
AIM ImmunoTech 表示安普利近在肿瘤学杂志上被列为 COVID-19 癌症患者的治疗选择
MT Newswires · 6天前
AIM ImmunoTech 强调在同行评审的癌症杂志中的 Ampligen 作为 SARS-CoV-2 癌症患者的潜在疗法
AIM ImmunoTech Inc. (NYSE:AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential
Benzinga · 6天前
思摩尔(06969.HK)附属续签协议 发展新型肺炎潜在吸入疗法
AAFN · 05/28 00:55
AIM扩大了合作伙伴关系,以促进Ampligen作为Covid-19疗法
By Matt Grossman AIM ImmunoTech Inc. has extended a research agreement with a subsidiary of Smoore International Holdings Ltd. as part of a project to...
marketwatch.com · 05/27 12:55
BRIEF-AIM Immunotech Announces Two Year Extension Of Agreement With Shenzhen Smoore Technology Limited To Develop And Test A New Inhalation Delivery Device For Ampligen
reuters.com · 05/27 12:46
AIM Immunotech扩大了与深圳Smoore的合作关系,以开发Ampligen作为潜在的COVID-19吸入疗法
MT Newswires · 05/27 11:13
Brief-Aim Immunotech宣布其鼻内1期临床试验的第三批研究的阳性安全性数据
reuters.com · 05/26 13:26
AIM ImmunoTech报告在第1阶段研究中完成了第3组的剂量,以评估安全性,耐受性和作为鼻内治疗剂的Ampligen的生物活性
AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy,
Benzinga · 05/26 13:16
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AIM最新的财务预测,通过AIM每股收益,每股净资产,每股现金流等数据分析AIM ImmunoTech Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AIM价格均价为6.50,最高价位8.00,最低价为5.00。
EPS
机构持股
总机构数: 15
机构持股: 9.35万
持股比例: 0.20%
总股本: 4,783.30万
类型机构数股数
增持
6
31
建仓
4
7.09万
减持
2
2,899
平仓
7
1.30万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.57%
制药与医学研究
-0.98%
高管信息
Chairman/Director
William Mitchell
President/Chief Executive Officer/Vice Chairman/General Counsel/Secretary/Director
Thomas Equels
Chief Financial Officer
Ellen Lintal
Chief Operating Officer/General Counsel/Secretary
Peter Rodino
Senior Vice President
Wayne Springate
Chief Scientific Officer
David Strayer
Director
Stewart Appelrouth
暂无数据
AIM 简况
AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

微牛提供AIM ImmunoTech Inc(AMEX-AIM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AIM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AIM股票基本功能。